Patient demographics
| Characteristics . | Values . |
|---|---|
| Total no. of patients | 41 |
| Median age, y (range) | 34 (14-84) |
| Sex, male/female | 25/16 |
| Cause of AA | |
| Idiopathic | 38 |
| After hepatitis | 3 |
| PNH clone (>1% GPI-AP deficient granulocytes) | 8 |
| Time analysis | |
| Patients at diagnosis | 21 |
| Severe AA | 16 |
| Moderate AA | 5 |
| Patients in complete remission | 13 |
| Anterior treatments | |
| hATG + CSA | 9 |
| rATG + CSA | 4 |
| hATG + CSA + mycophenolate mofetil | 2 |
| hATG + CSA + sirolimus | 1 |
| Campath | 4 |
| > 1 immunosuppressive courses | 3 |
| Duration follow-up since last treatment, y; median (range) | 3 (1-7) |
| Poor responders | 16 |
| Anterior treatments | |
| hATG + CSA | 15 |
| rATG + CSA | 10 |
| hATG + CSA + mycophenolate mofetil | 2 |
| hATG + CSA + sirolimus | 1 |
| Campath | 4 |
| Daclizumab | 1 |
| Alemtuzumab | 1 |
| Androgens (Danazol) | 3 |
| > 2 immunosuppressive courses | 12 |
| Patients off therapy at time of sampling (yes/no) | 7/9 |
| Transfusion status at time of sampling (yes/no) | 11/5 |
| Characteristics . | Values . |
|---|---|
| Total no. of patients | 41 |
| Median age, y (range) | 34 (14-84) |
| Sex, male/female | 25/16 |
| Cause of AA | |
| Idiopathic | 38 |
| After hepatitis | 3 |
| PNH clone (>1% GPI-AP deficient granulocytes) | 8 |
| Time analysis | |
| Patients at diagnosis | 21 |
| Severe AA | 16 |
| Moderate AA | 5 |
| Patients in complete remission | 13 |
| Anterior treatments | |
| hATG + CSA | 9 |
| rATG + CSA | 4 |
| hATG + CSA + mycophenolate mofetil | 2 |
| hATG + CSA + sirolimus | 1 |
| Campath | 4 |
| > 1 immunosuppressive courses | 3 |
| Duration follow-up since last treatment, y; median (range) | 3 (1-7) |
| Poor responders | 16 |
| Anterior treatments | |
| hATG + CSA | 15 |
| rATG + CSA | 10 |
| hATG + CSA + mycophenolate mofetil | 2 |
| hATG + CSA + sirolimus | 1 |
| Campath | 4 |
| Daclizumab | 1 |
| Alemtuzumab | 1 |
| Androgens (Danazol) | 3 |
| > 2 immunosuppressive courses | 12 |
| Patients off therapy at time of sampling (yes/no) | 7/9 |
| Transfusion status at time of sampling (yes/no) | 11/5 |